http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013310263-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_06c87200cf96acdabeae38cd1101927d
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6874
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B30-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B30-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F19-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6809
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B30-10
filingDate 2013-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7a6c0a641956cf1a091662b1073e620
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3b3fe8122ee754726b32e0dc7c402d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b70f2a26be1329344e80a19e58fdffb9
publicationDate 2013-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2013310263-A1
titleOfInvention Diagnosing cancer using genomic sequencing
abstract Methods, systems, and apparatus determine whether a first chromosomal region exhibits a deletion or an amplification associated with cancer in a sample from a subject (e.g., where the sample includes a mixture of cell-free DNA from tumor cells and non-malignant cells. Nucleic acid molecules of the biological sample are sequenced. Respective amounts of a clinically-relevant chromosomal region and of background chromosomal region(s) are determined from results of the sequencing. A parameter derived from these amounts (e.g. a ratio) is compared to one or more cutoff values, thereby determining a classification of whether first chromosomal region exhibits a deletion or an amplification associated with cancer.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11749381-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11603553-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018066306-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018031808-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3636777-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10626443-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11447829-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11525134-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3118324-A1
priorityDate 2007-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129472015
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412688
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398593

Total number of triples: 39.